Open Access

The future of lipid management: new therapies for LDL-C lowering

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Sponsored by National Lipid Association

Congress Session

About the speaker

Doctor Harold Bays

Louisville Metabolic and Atherosclerosis Research Center, Louisville (United States of America)
1 presentation
0 follower

4 more presentations in this session

Clinical implications for patients at persistent ASCVD risk

Speaker: Doctor J. Saseen (Aurora, US)


Clinical trial updates

Speaker: Doctor C. Ballantyne (Houston, US)


Post-activity quiz and discussion

Speaker: Doctor P. MORRIS (Charleston, US)


Questions and answers / Panel discussion


Access the full session

Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

Speakers: Doctor H. Bays, Doctor J. Saseen, Doctor C. Ballantyne, Doctor P. MORRIS

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

27 August 2021

Open Access

Will coronary atherosclerosis be eliminated?

27 August 2021

Open Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

This platform is supported by

logo Novo Nordisk